Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FATE	$1.19	+3.48%	760.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FATE	$1.19	+3.5%	760.00K
3
4
5
6

FATE

FATE

No Data Available

Get Fate Therapeutics Inc. Data in Excel

Get Fate Therapeutics Inc. Data in Excel